CoChat

Efficacy of chloroquine with primaquine for uncomplicated Plasmodium vivax malaria without G6PD testing in Northwest Ethiopia: a one-arm in vivo prospective therapeutic efficacy study

Open access

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; none of the 58 sources its claims cite is checked for support yet.

Abstract

BACKGROUND: The declining efficacy and widespread resistance to antimalarial drugs (AMD) pose significant challenges to global malaria control and elimination efforts. To enhance treatment efficacy, the World Health Organization (WHO) recommends the use of combination therapies. This study aimed to evaluate the therapeutic efficacy of chloroquine with primaquine (CQ-PQ) for the treatment of uncomplicated Plasmodium vivax malaria in the study area. METHODS: The study utilized a single-arm, 42-day follow-up design to assess the therapeutic efficacy and safety of a treatment regimen in Northwest Ethiopia. Participants, all diagnosed with uncomplicated vivax malaria, received a 3-day course of chloroquine (CQ) at 25 mg/kg, followed by a 14-day course of primaquine (PQ) at 0.25 mg/kg. Participants were monitored with follow-up visits on days 1, 2, 3, 7, 14, 21, 28, 35, and 42. Data were double-entered into a standard Excel sheet by the WHO and analysed using SPSS v.26. Statistical analyses included Kaplan-Meier survival analysis, t-tests, and ANOVA, with statistical significance set at p < 0.05. RESULTS: Of the 100 participants enrolled, 92% completed the study. The cumulative treatment success rate for CQ-PQ was 93.7% (95% CI 0.86-0.97) on day 42, with a 6.3% (95% CI 0.03-0.14) treatment failure rate. Asexual parasite clearance was rapid, with 97% achieving clearance by day 2 and full clearance by day 3 in all but one participant. Haemoglobin levels increased significantly from 12.3 g/dL at baseline to 13.5 g/dL by day 42, with 84.2% of mild anaemic patients and 85.7% of moderate anaemic patients showing recovery. Common adverse events included abdominal pain (8%) and diarrhea (5%), all of which resolved by day 7. CONCLUSION: CQ-PQ therapy demonstrated high efficacy in clearing parasitaemia and improving haemoglobin levels in patients with vivax malaria. These results highlight the potential of CQ-PQ as an effective treatment option, with a favourable safety profile. Further studies are needed to explore long-term outcomes and the impact of this treatment on malaria control in different settings.

Overview

CoChat Summary

TL;DR

In a single-arm, 42-day in vivo study in Northwest Ethiopia, chloroquine plus primaquine without G6PD testing achieved a day-42 PCR-uncorrected treatment success rate of 93.7% among 100 enrolled patients with uncomplicated *Plasmodium vivax* malaria. Parasite and fever clearance were rapid, haemoglobin improved, and no severe adverse events or dark urine were reported.

Key findings

  • The cumulative CQ–PQ treatment success rate was 93.7% (95% CI 86.4–97.1) on day 42 and 94.7% (95% CI 87.8–97.8) on day 28; treatment failure was 6.3% (95% CI 2.9–13.6) on day 42.
  • Asexual parasite clearance was rapid: 47% cleared by day 1, 97% by day 2, and all but one participant by day 3; gametocyte clearance was 73.8% by day 1 and 100% by day 3, with no gametocyte recurrence.
  • Mean haemoglobin increased from 12.3 ± 1.11 g/dL at baseline to 13.5 ± 1.126 g/dL by day 42 (p < 0.0001); 84.2% (16/19) of mild anaemic and 85.7% (6/7) of moderate anaemic patients improved, and anaemic patients decreased from 26 to 4.
  • No severe adverse events occurred; abdominal pain (8%) and diarrhoea (5%) were most common and resolved by day 7. No dark-coloured urine (Hillmen urine colour chart ≥ 5) was reported.

Methods

  • Single-arm, 42-day follow-up in vivo therapeutic efficacy and safety study at Andasa Health Center, Northwest Ethiopia, from November 2022 to March 2023.
  • Participants had uncomplicated *P. vivax* mono-infection, asexual parasitaemia ≥ 250/μL, age > 6 months, and lived within 10 km; 2,915 suspected malaria patients were screened, 271 had *P. vivax*, and 100 were enrolled, with 92% completing follow-up.
  • Treatment was CQ 25 mg/kg over 3 days plus PQ 0.25 mg/kg daily for 14 days, with follow-up on days 1, 2, 3, 7, 14, 21, 28, 35, and 42; outcomes were classified per WHO as ACPR, ETF, LCF, or LPF, and analysed with Kaplan–Meier survival analysis, t-tests, and ANOVA in SPSS v.26 (p < 0.05).

Limitations

  • The paper states there was no PCR genotyping to differentiate relapses from new infections, so results are PCR uncorrected, and no data on CQ drug concentrations were collected to distinguish true resistance from insufficient drug levels.
  • The text makes evident that the study was single-arm with no direct CQ monotherapy comparison arm, and it used a convenient sampling technique.
  • The study was conducted without G6PD testing; the authors note this was under close Hillmen urine monitoring and in a setting with low reported Ethiopian G6PD deficiency prevalence, but this remains a limitation for interpreting primaquine safety.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12936-025-05446-y

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Map of the study site. Bahir Dar zuria district, Andassa kebele
Fig. 1 Map of the study site. Bahir Dar zuria district, Andassa kebeleCC BY-NC-ND · PubMed Central
Fig. 2 Flow chart of study participants recruited and followed for 42 days, showing the number of participants assessed at each follow-up visit and final classification outcomes
Fig. 2 Flow chart of study participants recruited and followed for 42 days, showing the number of participants assessed at each follow-up visit and final classification outcomesCC BY-NC-ND · PubMed Central
Fig. 3 Kaplan–Meier Survival curve in CQ–PQ therapeutic efficacy study outcome
Fig. 3 Kaplan–Meier Survival curve in CQ–PQ therapeutic efficacy study outcomeCC BY-NC-ND · PubMed Central
Fig. 4 A line graph of asexual parasite and gametocyte clearance following CQ–PQ treatment
Fig. 4 A line graph of asexual parasite and gametocyte clearance following CQ–PQ treatmentCC BY-NC-ND · PubMed Central
Fig. 5 Haemoglobin recovery following CQ–PQ treatment
Fig. 5 Haemoglobin recovery following CQ–PQ treatmentCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

0 Valid · 2 Not valid · 40 Not checked · 80 Own results and interpretations

64 more claims

Create a free account to see all 122 claims and to verify the 58 references still open.

See all claims — free account
  • It may state two separate claims as one. 32
  • Probably not a substantial claim. 34
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 7 · the rest aren’t loaded

2 more findings

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Show all 37 references

Research works printed but not linked: 2

  1. WHO. World malaria report 2024. Geneva: World Health Organization; 2024.
  2. WHO. Malaria eradication: benefits, future scenarios and feasibility. A report of the strategic advisory group on malaria eradication. Geneva: World Health Organization; 2020.

Metadata

Authors
Getu, E., Biruksew, A., Eshetu, T., Abamecha, A., Assefa, D. G., Mohammed, H., Wuletaw, Y., Tasew, G., Tollera, G., Hailu, M., Kassa, M., Assefa, A., & Brhane, B. G.
Affiliations
  • Jimma University (ET)
  • Dilla University (ET)
Corresponding author
Getu, Eyob
Venue
Malaria Journal
Published
2025-06-15
Volume
24
Issue
1
Pages
192-192
ISSN
1475-2875 (ISSN-L)
OpenAlex
W4411317764
Cited by
4
References
37
Citations by year
2026: 3 · 2025: 1
FWCI
2.31
Type
journal article
Language
en
Open access
Licence
Locations
  • Malaria Journal (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Phytochemical compounds biological activities
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Travel-related health issues
Keywords
vivax malaria, chloroquine, primaquine, combination antimalarial therapy, treatment efficacy, hemoglobin, antimalarial drug resistance, G6PD testing, treatment safety, Northwest Ethiopia, malaria elimination, malaria elimination strategy
MeSH terms
Adolescent, Adult, Antimalarials, Child, Child, Preschool, Chloroquine, Drug Therapy, Combination, Ethiopia, Female, Humans, Male, Middle Aged, Plasmodium vivax, Primaquine, Prospective Studies, Malaria, Vivax, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of chloroquine with primaquine for uncomplicated Plasmodium vivax malaria without G6PD testing in Northwest Ethiopia: a one-arm in vivo prospective therapeutic efficacy study. https://app.cochat.ai/papers/10.1186/s12936-025-05446-y
The paper
Getu, E., Biruksew, A., Eshetu, T., Abamecha, A., Assefa, D. G., Mohammed, H., Wuletaw, Y., Tasew, G., Tollera, G., Hailu, M., Kassa, M., Assefa, A., & Brhane, B. G. (2025). Efficacy of chloroquine with primaquine for uncomplicated Plasmodium vivax malaria without G6PD testing in Northwest Ethiopia: a one-arm in vivo prospective therapeutic efficacy study. Malaria Journal. https://doi.org/10.1186/s12936-025-05446-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.